Latest Advances in Lung Cancer Research

New study reveals genetic factors protect some lifelong smokers from lung cancer, identifying robust mechanisms that limit mutation accumulation and improve early detection strategies

The Veterans Health Administration promotes lung cancer screening with low-dose CT scans for eligible veterans aged 50-80 with a 20+ pack-year smoking history.

The Lung Cancer Genetics Study aims to understand genetic factors in lung cancer, improving detection, risk reduction, and care through a collaborative research effort.

Wildfire smoke exposure increases lung cancer risk and worsens patient outcomes, particularly for vulnerable populations and those recovering from lung cancer surgery.

RYBREVANT and LAZCLUZE combination shows significant overall survival benefit in EGFR-mutated NSCLC patients, exceeding one year median survival improvement over standard osimertinib treatment.

Scientists develop a groundbreaking urine test that detects “zombie” cell proteins, enabling early detection of lung cancer and potentially improving patient outcomes and prognosis.

Osimertinib after surgery significantly improves survival in early-stage EGFR-mutated NSCLC, reducing cancer recurrence and offering a new standard of care.

Neoadjuvant chemotherapy before surgery significantly improves survival in stage IIIA NSCLC, reducing death risk by 30% and increasing 5-year survival to 41% from 26%.

Dr. David Carbone at Ohio State advances lung cancer treatment with immunotherapy and targeted therapies, providing compassionate, personalized care and hope to patients.

FDA approves Opdivo for early-stage NSCLC. This immunotherapy can be used before and after surgery, potentially improving outcomes for patients with resectable lung cancer.

New therapies for EGFR-mutant lung cancer boost survival rates. Researchers combat drug resistance and aim for tailored treatments to enhance patient care and quality of life.